NIACINAMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H6N2O
Molecular Weight	122.1249
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1cc(cnc1)C(=N)O

InChI

InChIKey=DFPAKSUCGFBDDF-UHFFFAOYSA-N

InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

HIDE SMILES / InChI

Description
Sources: http://www.mayoclinic.org/drugs-supplements/niacin--niacinamide/evidence/hrb-20059838
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/4244068

Niacinamide, known as nicotinamide, is an important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Pellagra is a nutritional disease that occurs due to insufficient dietary amounts of vitamin B3 or the chemical it is made from (tryptophan). Symptoms of pellagra include skin disease, diarrhea, dementia, and depression. In addition, was experiments, revealed, that niacinamide hydroiodide might have role in ophthalmology and parenteral use of niacinamide hydroiodide can treat arteriosclerotic syndromes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
NAD-dependent deacetylase sirtuin 2 4 Target ID: CHEMBL4462 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700324	Inhibitor 7728	11.0 µM [IC50]
NAD-dependent deacetylase sirtuin 1 13 Target ID: CHEMBL4506 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700324	Inhibitor 7728	100.0 µM [IC50]
NAD-dependent deacetylase sirtuin 3 4 Target ID: CHEMBL4461 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700324	Inhibitor 7728	14.0 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Ophthalmology 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4244068	Primary	Not Provided 492	Unknown Approved Use Unknown
Arteriosclerotic syndromes 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13347482	Primary	Not Provided 492	Unknown Approved Use Unknown
Pellagra 3 Sources: http://www.webmd.com/vitamins-supplements/ingredientmono-924-niacin%20and%20niacinamide%20vitamin%20b3.aspx?activeingredientid=924&	Preventing	Approved 8043	Niacinamide Approved Use Treatment and prevention of niacin deficiency, and certain conditions related to niacin deficiency such as pellagra.

C_max

Value	Dose	Co-administered	Analyte	Population
213.2 ng/mL EXPERIMENT https://link.springer.com/article/10.1365/s10337-010-1645-3	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: LOVASTATIN	LOVASTATIN	NIACINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
2669 ng × h/mL EXPERIMENT https://link.springer.com/article/10.1365/s10337-010-1645-3	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: LOVASTATIN	LOVASTATIN	NIACINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
15.9 h EXPERIMENT https://link.springer.com/article/10.1365/s10337-010-1645-3	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: LOVASTATIN	LOVASTATIN	NIACINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
6 g single, oral Highest studied dose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136	healthy, 27-45 n = 6 Health Status: healthy Age Group: 27-45 Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136	Other AEs: Vomiting... Other AEs: Vomiting Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136
80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	unhealthy, 41-82 n = 40 Health Status: unhealthy Condition: Head and neck cancer Age Group: 41-82 Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	DLT: Nausea... Disc. AE: Nausea, Toxicity renal... Dose limiting toxicities: Nausea (severe, 17.5%) AEs leading to discontinuation/dose reduction: Nausea (20%) Toxicity renal (2.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69
80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 54-81 n = 7 Health Status: unhealthy Condition: Head and neck cancer Age Group: 54-81 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116
100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	DLT: Hypotension, Oliguria... Disc. AE: Nausea, Vomiting... Dose limiting toxicities: Hypotension (severe, 50%) Oliguria (50%) AEs leading to discontinuation/dose reduction: Nausea (severe, 50%) Vomiting (severe, 50%) Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116

AEs

AE	Significance	Dose	Population
Vomiting		6 g single, oral Highest studied dose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136	healthy, 27-45 n = 6 Health Status: healthy Age Group: 27-45 Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/8356223 Page: p.136
Toxicity renal	2.5% Disc. AE	80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	unhealthy, 41-82 n = 40 Health Status: unhealthy Condition: Head and neck cancer Age Group: 41-82 Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69
Nausea	20% Disc. AE	80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	unhealthy, 41-82 n = 40 Health Status: unhealthy Condition: Head and neck cancer Age Group: 41-82 Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69
Nausea	severe, 17.5% DLT	80 mg/kg 1 times / day multiple, oral MTD Dose: 80 mg/kg, 1 times / day Route: oral Route: multiple Dose: 80 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69	unhealthy, 41-82 n = 40 Health Status: unhealthy Condition: Head and neck cancer Age Group: 41-82 Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/9165139 Page: p.69
Oliguria	50% DLT	100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116
Hypotension	severe, 50% DLT	100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116
Nausea	severe, 50% Disc. AE	100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116
Vomiting	severe, 50% Disc. AE	100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116	unhealthy, 75-82 n = 2 Health Status: unhealthy Condition: Head and neck cancer Age Group: 75-82 Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/7607932 Page: p.1116

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1467	inhibitor 1604	inhibitor 1702

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1383 CYP2E1 790	CYP2E1 606 CYP2A6 485 CYP2B6 616	CYP1A2 637

Drug as perpetrator

Target	Modality	Activity
CYP2E1 871	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 13000 uM]
CYP3A4 1772	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 13000 uM]
CYP2D6 1738	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 3800 uM]
CYP1A2 1532	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 44000 uM]
CYP2C9 1648	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/15081432/ Page: 3.0	yes [Ki 51000 uM]
CYP1A1 192	supressor 140 Sources: https://pubmed.ncbi.nlm.nih.gov/7508708/	yes
CYP1A2 1532	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/7508708/	yes

Drug as victim

Target	Modality	Activity
CYP2A6 485	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583486/	no
CYP2B6 616	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583486/	no
CYP2E1 606	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583486/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY583359	https://www.001chemical.com/chem/98-92-0
3B Scientific (Wuhan) Corp	3B1-00061	http://www.3bsc.com/index/pro_info.php?id=20273
3B Scientific (Wuhan) Corp	3B3-029729	http://www.3bsc.com/index/pro_info.php?id=50986
AA Blocks	AA00IJXK	http://www.aablocks.com/goods/Goods/detail?id=AA00IJXK
AHH Chemical co.,ltd	MT-19649	http://www.ahhchemical.com/product/MT-19649.html
AHH Chemical co.,ltd	NP-1178	http://www.ahhchemical.com/product/NP-1178.html
AK Scientific, Inc. (AKSCI)	J10422	http://www.aksci.com/item_detail.php?cat=J10422
AK Scientific, Inc. (AKSCI)	K774	http://www.aksci.com/item_detail.php?cat=K774
Aaron Chemicals	AR00IKPC	http://www.aaronchem.com/98-92-0
AbMole Bioscience	M4896	http://www.abmole.com/products/nicotinamide.html
Acadechem	ACDC-066615	http://acadechemical.com/product/8348
Acadechem	ACDS-017518	http://www.acadechemical.com/product/92217
Achemica	ACMC-20aizz	http://www.achemica.com/prodinfo/?id=137848
Achemtek	0104-014668	http://www.achemtek.com/98-92-0
Acros Organics	AC128270025	https://www.fishersci.com/shop/products/nicotinamide-98-acros-organics-2/AC128270025
Acros Organics	AC128271000	https://www.fishersci.com/shop/products/nicotinamide-98-acros-organics/AC128271000
Acros Organics	AC128275000	https://www.fishersci.com/shop/products/nicotinamide-98-acros-organics/AC128275000
Alfa Aesar	A15970	https://www.alfa.com/en/catalog/A15970/
Alfa Chemistry	AP98920-B	https://reagents.alfa-chemistry.com/product/niacinamide-cas-98-92-0-19137.html
Alfa Chemistry	AP98920-A	https://reagents.alfa-chemistry.com/product/nicotinamide-vitamin-b3-solution-cas-98-92-0-19136.html
Alfa Chemistry	1255150-40-3	https://www.alfa-chemistry.com/cas_1255150-40-3.htm
Alfa Chemistry	ACM98920-1	https://www.alfa-chemistry.com/nicotinamide-cas-98-92-0-item-284990.htm
Alichem	29205886	http://www.alichem.com/en/products/98-92-0.html
Angene	AGN-PC-0084Q1	http://www.angenechemical.com/productshow/AGN-PC-0084Q1.html
Anward	ANW-75549	http://www.anward.com/pro_result/62000
ApexBio Technology	N1651	http://www.apexbt.com/nicotinamide-14369.html
Aurora Fine Chemicals LLC	A00.297.461	http://online.aurorafinechemicals.com/info?ID=A00.297.461
Aurora Fine Chemicals LLC	K02.105.372	http://online.aurorafinechemicals.com/info?ID=K02.105.372
Aurum Pharmatech LLC	W-3583	http://www.Aurumpharmatech.com/Product/ProductDetails/W_3583
Avantor Inc	200000-710	https://us.vwr.com/store/product/7514772/nicotinamide
Avantor Inc	200013-660	https://us.vwr.com/store/product/7514772/nicotinamide
BLD Pharm	BD42146	http://www.bldpharm.com/products/98-92-0.html
BOC Sciences	113950-01-9	https://isotope.bocsci.com/product/nicotinamide-amide-15n-cas-113950-01-9-344937.html
BOC Sciences	347841-88-7	https://www.bocsci.com/nicotinamide-d4-cas-347841-88-7-item-110701.html
BioChemPartner	BCP07322	http://www.biochempartner.com/98-92-0-BCP07322
BioCrick	BCN1025	http://www.biocrick.com/Nicotinamide-BCN1025.html
BioSynth	Q-201470	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201470.html
Boerchem	BC676662	http://www.boerchem.com/?product_39381.html
CSNpharm	CSN16796	https://www.csnpharm.com/products/nicotinamide.html
Chem Scene	CS-1968	http://www.chemscene.com/98-92-0.html
ChemFaces	CFN99926	http://www.chemfaces.com/natural/Nicotinamide-CFN99926.html
ChemMol	44009502	http://www.chemmol.com/chemmol/44009502.html
ChemMol	49417291	http://www.chemmol.com/chemmol/49417291.html
Chemspace	CSSB00000162173	https://chem-space.com/CSSB00000162173
China MainChem Co., Ltd	98-92-0	https://www.mainchem.com/product/china-nicotinamide-supplier-vitamin-b3-manufacturer/
China MainChem Co., Ltd	MS98-92-0	https://www.mainchem.com/product/nicotinamide/
Clearsynth	CS-O-30679	http://www.clearsynth.com/en/CSO30679.html
Clearsynth	CS-EB-01471	https://www.clearsynth.com/en/CSEB01471.html
Clearsynth	CS-ER-01463	https://www.clearsynth.com/en/CSER01463.html
DC Chemicals	DCY-061	http://www.dcchemicals.com//product_show-Nicotinamide.html
Debye Scientific	DB-057754	http://www.debyesci.com/cas_98-92-0.html
EMD Biosciences	481907	http://www.emdbiosciences.com/products/EMD_BIO-481907
EMD Millipore	481907	http://www.emdbiosciences.com/products/EMD_BIO-481907
Enamine	Z33546463	https://www.enaminestore.com/catalog/Z33546463
Finetech	FT-0773644	http://www.finetechnology-ind.com/prod/detail/pub/10119-18-3.html
Finetech	FT-0672696	http://www.finetechnology-ind.com/prod/detail/pub/347841-88-7.html
Finetech	FT-0631517	http://www.finetechnology-ind.com/product/All%20product%20List/98-92-0.html
Glentham Life Sciences	GP9253	http://www.glentham.com/products/product/GP9253/
Hairui	HR135206	http://www.hairuichem.com/en/product/98-92-0.html
LGC Standards	DRE-A15519500AL-10	https://www.lgcstandards.com/US/en/p/DRE-A15519500AL-10
LGC Standards	DRE-C15519500	https://www.lgcstandards.com/US/en/p/DRE-C15519500
LGC Standards	LGCAMP0552.00-01	https://www.lgcstandards.com/US/en/p/LGCAMP0552.00-01
LGC Standards	LGCFOR0552.00	https://www.lgcstandards.com/US/en/p/LGCFOR0552.00
LGC Standards	MM0552.00-0250	https://www.lgcstandards.com/US/en/p/MM0552.00-0250
Lab Network	LN00195184	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00195184
Matrix Scientific	139707	https://www.matrixscientific.com/139707.html
MedChem Express	HY-B0150	https://www.medchemexpress.com/Nicotinamide.html
Molcore	MC583359	https://www.molcore.com/product/98-92-0
MuseChem	A000452	https://www.musechem.com/product/A000452.html
Oakwood	239905	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=120904&ExtHyperLink=1
Parchem	11995	http://www.parchem.com/chemical-supplier-distributor/Niacinamide-001995.aspx
Renno Tech	RP18130	http://www.rennotech.com/product_show.asp?id=23996
Sigma-Aldrich	72345_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/72345?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	72347_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/72347?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	72340_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/72340?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	47865-U_SUPELCO	https://www.sigmaaldrich.com/catalog/product/supelco/47865u?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1462006_USP	https://www.sigmaaldrich.com/catalog/product/usp/1462006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S001861	http://www.sinfoobiotech.com/product/1005259
Smolecule	S537140	http://www.smolecule.com/products/s537140
TCI (Tokyo Chemical Industry)	N0078	http://www.tcichemicals.com/eshop/en/us/commodity/N0078/index.html
THE BioTek	bt-277049	https://www.thebiotek.com/product/inhibitors/bt-277049
Tocris	4106	https://www.tocris.com/products/nicotinamide_4106
Vitas-M Laboratory	BBL013003	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL013003&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
VladaChem	VL143553	https://www.vladachem.com/product.php?products=98-92-0
VladaChem	VL164029	https://www.vladachem.com/product.php?products=98-92-0
VladaChem	VL261825-100G	https://www.vladachem.com/product.php?products=98-92-0
Yuhao Chemical	XJ0261	http://www.chemyuhao.com/98-92-0.html
abcr GmbH	AB118154	http://www.abcr.com/shop/en/AB118154
eNovation Chemicals	D409297	http://www.enovationchem.com/productDetails.asp?productID=D409297
mcule	MCULE-3532732201	https://mcule.com/MCULE-3532732201/

PubMed

Title	Date	PubMed
Lessons to be learned from studying Vibrio cholerae in model systems.	2001	11532208
Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT).	2001	11393553
The nitrilase superfamily: classification, structure and function.	2001	11380987
Elevation of blood NAD level after moderate exercise in young women and mice.	2001 Apr	11508711
The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone.	2001 Apr	11359455
Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols.	2001 Apr	11332037
Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide.	2001 Apr	11309246
Enhanced maturation of porcine neonatal pancreatic cell clusters with growth factors fails to improve transplantation outcome.	2001 Apr 27	11374418
Ca(2+)-calmodulin antagonist chlorpromazine and poly(ADP-ribose) polymerase modulators 4-aminobenzamide and nicotinamide influence hepatic expression of BCL-XL and P53 and protect against acetaminophen-induced programmed and unprogrammed cell death in mice.	2001 Aug 1	11461765
NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer.	2001 Aug 3	11371558
Cannabinoid receptors are absent in insects.	2001 Aug 6	11447587
Oxidative changes in brain pyridine nucleotides and neuroprotection using nicotinamide.	2001 Feb 16	11342263
Homoserine dehydrogenase from Saccharomyces cerevisiae: kinetic mechanism and stereochemistry of hydride transfer.	2001 Jan 12	11341915
Ternary complexes of liver alcohol dehydrogenase.	2001 Jan 30	11306059
Molecular dynamics simulation of class 3 aldehyde dehydrogenase.	2001 Jan 30	11306044
Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages.	2001 Jul	11461969
Allosteric activation of pyruvate kinase via NAD+ in rat liver cells.	2001 Jul	11453987
Characterization of poly(ADP-ribose)polymerase from Crithidia fasciculata: enzyme inhibition by beta-lapachone.	2001 Jul	11420111
Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide.	2001 Jul-Aug	11448590
Significance of interferon-gamma in coronary artery bypass surgery.	2001 Jul-Sep	11548832
[Effect of feeding with a poisonous mushroom Clitocybe acromelalga on the metabolism of tryptophan-niacin in rats].	2001 Jun	11577392
[Ring cleavage of N-arylpyridinium salts by nucleophiles--regioselectivity and stereochemistry of the products. 2].	2001 Jun	11446163
Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.	2001 Jun	11353811
Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide.	2001 Jun	11353795
Characterization of multicomponent monosaccharide solutions using an enzyme-based sensor array.	2001 Jun 15	11399030
Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility.	2001 Jun 15	11390466
Erythromycin biosynthesis. The 4-pro-S hydride of NADPH is utilized for ketoreduction by both module 5 and module 6 of the 6-deoxyerythronolide B synthase.	2001 Jun 18	11412964
An NMR-based metabonomic approach to the investigation of coelomic fluid biochemistry in earthworms under toxic stress.	2001 Jun 29	11434921
Probing catalysis by Escherichia coli dTDP-glucose-4,6-dehydratase: identification and preliminary characterization of functional amino acid residues at the active site.	2001 Jun 5	11380254
Evolution of the aldose reductase-related gecko eye lens protein rhoB-crystallin: a sheep in wolf's clothing.	2001 Mar	11428461
Effects of nicotinamide, an inhibitor of PARS activity, on gut and liver O2 exchange and energy metabolism during hyperdynamic porcine endotoxemia.	2001 Mar	11355130
Dietary vitamin K1 requirement and comparison of biopotency of different vitamin K sources for young turkeys.	2001 May	11372711
Purification and structure of the major product obtained by reaction of NADPH and NMNH with the myeloperoxidase/hydrogen peroxide/chloride system.	2001 May	11358505
Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders.	2001 May	11357946
Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide.	2001 May 11	11426841
Fatty acid amide hydrolase inhibition by neurotoxic organophosphorus pesticides.	2001 May 15	11350214
Characterization of the hydroxypropylmethylcellulose-nicotinamide binary system.	2001 May 21	11337164
Characterization and manipulation of the acyl chain selectivity of fatty acid amide hydrolase.	2001 May 22	11352748
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain.	2001 Nov 16	11518719
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.	2001 Oct	11606325
Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems.	2001 Oct	11561096
Contributions of valine-292 in the nicotinamide binding site of liver alcohol dehydrogenase and dynamics to catalysis.	2001 Oct 23	11601993
A dinucleotide repeat polymorphism at the poly(ADP-ribose) polymerase gene is not associated with predisposition to type 1 diabetes in French Caucasians.	2001 Sep	11591122
Prospects for predicting and stopping the development of type 1 of diabetes.	2001 Sep	11554777
A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus.	2001 Sep	11522594
Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide.	2001 Sep 1	11585048
Effect of nicotinamide on the properties of aqueous HPMC solutions.	2001 Sep 11	11532570
Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes.	2001 Sep 15	11556820
13C NMR analysis of electrostatic interactions between NAD+ and active site residues of UDP-galactose 4-epimerase: implications for the activation induced by uridine nucleotides.	2001 Sep 18	11551228
NAD+-dependent DNA ligase encoded by a eukaryotic virus.	2001 Sep 28	11459847

Patents

Sample Use Guides

In Vivo Use Guide

For mild vitamin B3 deficiency, niacin or niacinamide 50-100 mg per day is used. For pellagra in adults, niacin or niacinamide 300-500 mg daily is given in divided doses. For pellagra in children, niacin or niacinamide 100-300 mg daily is given in divided doses. For Hartnup disease, niacin or niacinamide 50-200 mg daily.

Route of Administration: Oral

In Vitro Use Guide

10 mM Niacinamide inhibited Resveratrol-mediated ROS suppression in B16F1 melanoma cells

Name

Type

Language

NIACINAMIDE

Official Name

English

TPN COMPONENT NIACINAMIDE

Common Name

English

NIACINAMIDE [HSDB]

Common Name

English

NIACIN (AS NIACINAMIDE) [VANDF]

Common Name

English

NICOTINAMIDE

Official Name

English

NSC-13128

Code

English

NICOTINAMIDUM

Common Name

English

NICOTINAMIDE [INN]

Common Name

English

NICOTINAMIDE [EP MONOGRAPH]

Common Name

English

NICOTINAMIDE [EP]

Common Name

English

NICOTINAMIDE [WHO-DD]

Common Name

English

NICOTINAMIDE [WHO-IP]

Common Name

English

NIACINAMID

Common Name

English

NICOTINAMIDE [MART.]

Common Name

English

NIACINAMIDE COMPONENT OF TPN

Common Name

English

NIACINAMIDE [INCI]

Common Name

English

NSC-27452

Code

English

NICOTINAMIDE [MI]

Common Name

English

NIACINAMIDE [VANDF]

Common Name

English

NIACINAMIDE [II]

Common Name

English

NIACINAMIDE [USP-RS]

Common Name

English

NIACINAMIDE [USP]

Common Name

English

NIACINAMIDE [FCC]

Common Name

English

NICOTINAMIDUM [WHO-IP LATIN]

Common Name

English

NICOTINAMIDUM [HPUS]

Common Name

English

NIACINAMIDE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A11HA01